Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Mother-Daughter Project (Merck-4)
NCT07240220Not yet recruiting
- Sponsor
- Indiana University
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of recombinant human papillomavirus 9-valent vaccine in cervical dysplasia (CIN) and human papillomavirus infection (2 arms), sponsored by Indiana University. Primary endpoints: Detection of CIN2/3, Local knowledge and attitudes and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical dysplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT07240220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240220.